Celltrion Reports Results of Regdanvimab (CT-P59) in Pre-Clinical Study Against the South African Variant (B.1.351)

 Celltrion Reports Results of Regdanvimab (CT-P59) in Pre-Clinical Study Against the South African Variant (B.1.351)

Celltrion Reports Results of Regdanvimab (CT-P59) in Pre-Clinical Study Against the South African Variant (B.1.351)

Shots:

  • The preclinical results have demonstrated that CT-P59 has neutralizing effect against the South African variant and showed a reduction in viral load of SARS-CoV-2 and in binding affinity against RBD in the three mutations of the South African variant
  • The company has completed patient enrolment of 1,300 people in an ongoing P- III trial evaluating the efficacy & safety of CT-P59 in 13 countries including the US, Spain, and Romania
  • The company will continue to investigate the neutralizing Abs and other responses to protect against current SARS-CoV-2 strains and emerging variants

Click here to­ read full press release/ article | Ref: Businesswire | Image: Celltrion

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post